Tissue patches are routinely used in surgery for soft tissue repair and reconstruction throughout the body in cardiovascular, orthopedic, abdominal and thoracic wall applications.
Current therapies are predominantly xenogeneic, allogeneic or synthetic biomaterials such as bovine pericardium, ePTFE, small intestinal submucosa, and dermal grafts. However, issues persist: incomplete tissue remodeling, mechanical mismatch, and reduced vascularity.
TRUE™ Patch has been developed to overcome these limitations and deliver a 100% biological soft tissue replacement that is:
- Acellular and non-immunogenic human cell-derived matrix
- Regenerative through robust host cell recruitment
- Suitable for a range of applications through highly tunable mechanical properties, sizes and shapes
TRUE™ Patch is suitable for a wide range of clinical applications:
TRUE™ Patch vs. Pericardium
Side by side testing of porcine pericardial tissue and TRUE Patch tissue demonstrates no mechanical compromise while delivering superior long term solution (Syedain et al, Heart Valve Society Presentation 2019).
Vascudyne Receives BioBusiness Award from Regenerative Medicine Minnesota for Treatment of Nerve Injury
Vascudyne Announces Presentation of First Clinical Results of TRUE AVC™ in Hemodialysis Access at the VASA Conference
Vascudyne’s CSO presents at the Heart Valve Society Meeting on tissue remodeling of engineered valved conduit evaluated at 52 weeks in the growing lamb
Copyright 2021 | Vascudyne, Inc.